The FDA Is On A Quest To Rid DTC Drug Ads Of Confounding Fine Print

Forbes: In February, the FDA proposed that pharma companies should no longer be required to run endless pages of fine print describing potential side effects of their drugs in direct-to-consumer (DTC) print ads. Anyone who regularly reads newspapers and magazines has seen what the agency is targeting: the reams of confounding, clinically worded caveats that most people need a magnifying glass to read—and an M.D. or Ph.D. to understand.

Read article